Analyst firms · UBS · SNN
UBS SNN price target and rating history
Smith & Nephew SNATS Inc. (SNN) · Health Care
UBS rates Smith & Nephew SNATS Inc. (SNN) Neutral, as of its latest action on Mar 12, 2025. It has published 4 rating actions on SNN since November 2022, including 2 upgrades and 2 downgrades.
- Current rating
- Neutral
- Price target
- Not stated
- Median target, all firms
- Too few
- Actions on SNN
- 4
Every UBS rating on SNN
- Mar 12, 2025DowngradeUBS downgrades to Neutral from Buy
- Jun 5, 2024
- Aug 8, 2023
- Nov 28, 2022DowngradeUBS downgrades to Sell from Neutral
How other firms rate SNN
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| BofA Securities | Neutral | Sep 8, 2026 | |
| Morgan Stanley | Equal-Weight | Sep 2, 2026 | |
| BTIG | Neutral | Aug 31, 2026 | |
| Barclays | Underweight | Aug 5, 2026 | |
| Kepler Cheuvreux | Hold | Jun 4, 2026 | |
| RBC Capital Markets | Sector Perform | Dec 15, 2025 |
Questions about UBS and SNN
- What is UBS's rating on SNN?
- UBS rates SNN Neutral, a neutral rating, as of Mar 12, 2025.
- When did UBS last change its view on SNN?
- On Mar 12, 2025, UBS downgrades to Neutral from Buy.
More SNN rating histories
All UBS ratingsSNN news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.